Abstract Rationale: FK506 inhibits calcineurin activity, resulting in the inhibition of calcium-dependent intracellular processes. Recent studies have suggested that intracellular calcium is likely to be involved in methamphetamine (MAP)-induced locomotor activity and stereotyped behavior, and in the development of sensitization to MAP. Objectives: We investigated the effects of FK506 on MAP-induced behavioral changes and the development of sensitization in rats. Methods: In experiment 1, animals were administered IP 2 mg/kg FK506 or vehicle followed 10 min later by MAP (1, 2, 4 and 8 mg/kg, IP). Another set of animals were administered FK506 (0.1, 2, 5 and 10 mg/kg) followed by 2 mg/kg MAP. Locomotor activity and stereotyped behavior were assessed. In experiment 2, animals received repeated IP injections of 2 mg/kg MAP pretreated with 2 mg/kg FK506 or vehicle for 5 consecutive days. One week later, rats were challenged with 1 mg/kg MAP. Results: Pretreatment with 2 mg/kg FK506 caused a rightward shift of the inverted U-shaped response curve of the locomotor activity induced by 1-8 mg/kg MAP. The same pretreatment significantly attenuated augmentation of the MAP-induced stereotyped behavior. FK506 at doses of 0.1-10 mg/kg dose-dependently inhibited the behavioral response induced by 2 mg/kg MAP. Coadministration of 2 mg/kg FK506 with 2 mg/kg MAP for 5 consecutive days resulted in significant suppression of the behavioral response to challenge with 1 mg/kg MAP. Conclusions: These results suggest that calcineurin plays an important role in MAP-induced behavioral changes and sensitization, especially the latter.
Introduction
Abuse of methamphetamine (MAP) (Glittenberg and Anderson 1999; Shaw 1999 ) and amphetamine (Baberg et al. 1996) is increasing worldwide. A single large dose or chronic use of MAP (Sato et al. 1983) or amphetamine (Robinson and Becker 1986) causes psychotic symptoms similar to paranoid schizophrenia. In animals, both MAP (Sato et al. 1992 ) and amphetamine (Randrup and Munkvad 1974) induce hyperlocomotion at lower doses, and stereotyped behavior at higher doses. The behavioral changes induced by MAP (Nishikawa et al. 1983) or amphetamine (Robinson and Becker 1986) are augmented by repetitive administration of the drugs, a phenomenon known as "behavioral sensitization". The behavioral sensitization in animals may share some common mechanisms with the psychotic state in humans induced by habitual intake of MAP (Sato et al. 1992) or amphetamine (Robinson and Becker 1986) . Although the detailed mechanisms underlying the behavioral responses induced by psychostimulants and behavioral sensitization to them are not known, they have been suggested to involve the mesolimbic and/or nigrostriatal dopaminergic systems (Robinson and Becker 1986; Kalivas and Stewart 1991; Wolf et al. 1994) . Specifically, both MAP (Kazahaya et al. 1989 ) and amphetamine (Giros et al. 1996) increase dopamine levels in synaptic clefts in the striatum and the nucleus accumbens, and the blockade of either dopamine D 1 -or D 2 -like receptors has been reported to attenuate behavioral acute responses and sensitization to MAP (Iorio et al. 1983; Ujike et al. 1989) or amphetamine (Christensen et al. 1984; Mailman et al. 1984) .
Stimulation of dopamine D 1 -like receptors increases cyclic adenosine 3′,5′-monophosphate (cAMP) levels by activating adenylate cyclase (Kebabian and Calne 1979; Seeman and Grigoriadis 1987) . Dopamine D 2 -like receptors are neither linked to adenylate cyclase nor to inhibition of its activity, and the activation of dopamine D 2 -like receptors may induce increases in intracellular calcium levels and activation of calcineurin in neostriatal neurons (Nishi et al. 1997) . It has been reported that MAP administration does not change striatal cAMP levels, but coadministration of rolipram, a cAMP phosphodiesterase type IV inhibitor, has been shown to antagonize MAP-induced behavioral changes and sensitization (Iyo et al. 1995 (Iyo et al. , 1996 . On the other hand, calcium channel blockers are known to suppress the behavioral sensitization to MAP (Hori et al. 1998) or amphetamine (Karler et al. 1991; Ansah et al. 1993) . Furthermore, it has been reported that activation of N-methyl-Daspartate (NMDA) receptors increases intracellular calcium levels in the striatum (Halpain et al. 1990 ) and that MK-801, a non-competitive NMDA receptor antagonist, attenuates the development of behavioral sensitization to MAP . These findings suggest that intracellular cAMP and calcium are likely to be involved in MAP-induced behavioral changes and the development of sensitization. FK506 (tacrolimus), an immunosuppressive agent, is widely used in organ transplantation (Snyder et al. 1998) . It binds to a family of proteins, including FK506 binding protein, and then inhibits calcineurin activity (Dawson et al. 1994) resulting in the inhibition of calcium-dependent intracellular processes. These proteins have been reported to be abundant in the brain (Dawson et al. 1994) ; however, the effects of FK506 on the central nervous system (CNS) and CNS-mediated behavior have yet to be determined (Snyder et al. 1998) .
In this study, we investigated the effects of FK506 on the behavioral changes induced by MAP and on the development of behavioral sensitization to MAP in rats, to clarify the roles of FK506 and calcineurin in CNS-mediated behavior.
Materials and methods

Animals
Male Wistar rats weighing 200-220 g were used. The animals were housed in groups of three per cage. They were maintained under standard conditions (12 h-12 h light-dark cycle: lights on from 0700 to 1900 hours; room temperature, 22±2°C; humidity, 55±5%) with free access to food and water for at least 1 week before the experiments. Experiments were performed in accordance with the principles of laboratory animal care (NIH publication No.85-23, revised 1985) . Drugs FK506 was dissolved in Tween 60 (polyoxyethylene sorbitan monostearate) diluted with saline. MAP was dissolved in saline. All drugs were injected intraperitoneally in a volume of 1 ml/kg body weight on each occasion. FK506 was a gift from Fujisawa Co., Japan, and other chemicals were purchased from commercial sources.
Measurement of locomotor activity
Locomotor activity was measured using an animal movement analysis system (Scanet SV-10; Matys, Toyama, Japan) (Asakura et al. 1992) . The system consisted of a rectangular enclosure (480×300 mm). The side walls (height, 60 mm) of the enclosure were equipped with 144 pairs of photosensors located at 5-mm intervals at a height of 30 mm from the bottom edge. A rectangular, transparent plastic cage, with an internal floor area of 440×260 mm and a height of 400 mm, was set on the Scanet SV-10 such that the photosensors were 30 mm above the floor of the cage. An animal was placed in the observation cage 1 h before drug treatment. Following treatment, a pair of photosensors was scanned every 0.1 s to detect the animal's movements. The intersection of paired photosensors (10 mm apart) in the enclosure was counted as one unit of locomotor activity. Data collected for 90 min were used for analysis.
Assessment of stereotyped behavior
The intensity of stereotyped behavior was assessed using the classification method of Akiyama et al. (1982) as follows: 0, asleep or still; 1, locomotion with normal exploration and normal pattern of sniffing; 2, hyperlocomotion with repetitive exploratory behavior, rearing, or increased rate of sniffing; 3, discontinuous sniffing with periodic locomotion activity; and 4, continuous compulsive sniffing without locomotion. Following drug treatment, the intensity of stereotyped behavior was assessed every 10 min for periods of 1 min by an observer blind to the treatment. The sum of nine consecutive intensity scores was used for data analysis. (1, 2, 4 and 8 mg/kg) Ninety animals were each given two injections. Animals were divided into those that were given Tween 60 solution (vehicle of FK506) as the first injection (T group animals, n=45) and those that received 2 mg/kg FK506 as the first injection (F group animals, n=45). In the T group, injection of Tween 60 solution was followed by saline (vehicle of MAP) (n=9), 1 mg/kg MAP (n=9), 2 mg/kg MAP (n=9), 4 mg/kg MAP (n=9) or 8 mg/kg MAP (n=9). Similarly, the F group animals received saline alone (n=9), 1 mg/kg MAP (n=9), 2 mg/kg MAP (n=9), 4 mg/kg MAP (n=9) or 8 mg/kg MAP (n=9) as the second injection. The interval between the first and the second injections was 10 min. After the second injection, behavioral observations of locomotor activity and stereotyped behavior were begun.
Effects of various FK506 doses (0.1, 2, 5 and 10 mg/kg) on responses to 2 mg/kg MAP
A preliminary study showed that about half the animals died after a single administration of 15 mg/kg FK506, whereas no animals died after administration of doses of 10 mg/kg or lower. Therefore, 10 mg/kg was chosen as the maximum dose of FK506. At the doses tested, FK506 itself induced no identifiable toxic effects, including ataxia, apnea, cyanosis etc.
Ninety animals were each treated with two injections with an interval of 10 min. Animals were divided into those that received saline alone as the second injection (S group animals, n=45) and those that received 2 mg/kg MAP as the second injection (M group animals, n=45). As the first injection, both the S and M group animals received Tween 60 solution (n=9), 0.1 mg/kg FK506 (n=9), 2 mg/kg FK506 (n=9), 5 mg/kg FK506 (n=9) or 10 mg/kg FK506 (n=9). Behavioral assessment was started after the second injection.
Experiment 2: effects of FK506 on development of behavioral sensitization Thirty-six animals were divided into the following four groups: T/S (n=9), F/S (n=9), T/M (n=9), and F/M (n=9). The T/S group was given Tween 60 solution followed by saline, the F/S group 2 mg/kg FK506 followed by saline, the T/M group Tween 60 solution followed by 2 mg/kg MAP, and the F/M group 2 mg/kg FK506 followed by 2 mg/kg MAP. The interval between the first and second injections was 10 min. For each animal, the same treatment was continued for 5 consecutive days. Locomotor activity and stereotyped behavior were observed daily according to the procedures described above. One week after the last treatment, each animal was given 1 mg/kg MAP and the behavioral changes were observed.
Statistics
Mean comparisons in the behavioral assessment between two or more groups were evaluated by Student's t-test or one-way analysis of variance (ANOVA) followed by Fisher's protected least significant difference (PLSD) test. The dose-response relationship between the drugs and behavior was evaluated by one-way ANOVA with contrast (polynomial). P values <0.05 were considered statistically significant.
Results
Experiment 1: effects of FK506 on behavioral responses induced by single administration of MAP
Effects of 2 mg/kg FK506 on responses to various MAP doses (1, 2, 4 and 8 mg/kg)
Neither the T nor F group animals showed any changes in locomotor activity after administration of saline (Fig. 1, top) . After receiving 1 mg/kg MAP, rats in both the T and F groups showed significant increases in locomotor activity compared with the corresponding value after saline administration (P<0.001 for both groups). The F group showed a slightly, but not significantly reduced amount of locomotion after administration of 1 mg/kg MAP than the T group. Administration of 2 mg/kg MAP further enhanced locomotor activity in the T and F groups: the activity after 2 mg/kg MAP was markedly increased relative to that after administration of 1 mg/kg (P<0.001 for both groups). The level of the locomotor activity in the F group was significantly less than that in the T group (P<0.05). The level of locomotor activity after 4 mg/kg MAP was slightly but not significantly reduced in the T group compared with that after administration of 2 mg/kg MAP, although a small but not significant increase was noted in the F group. Thus, both groups showed similar levels of locomotor activity after administration of 4 mg/kg MAP. When 8 mg/kg MAP was given, locomotor activity in the T group was decreased significantly as compared with that after administration of 4 mg/kg (P<0.05). The F group also showed a similar and significant decrease (P<0.05). The value in the T group was significantly lower than that in the F group (P<0.05). Thus, both the T and F groups, when given MAP at 1, 2, 4 or 8 mg/kg, showed inverted U-shaped locomotor activity curves. The highest levels of activity were observed at 2 mg/kg of MAP in the T group, and 4 mg/kg in the F group.
In both the T and F groups, MAP intensified the stereotyped behavior in a dose-dependent manner [T group, F(1,35)=106.1, P<0.0001; F group, F(1,35)=259.9, P<0.0001] (Fig. 1, bottom) . At each of the four MAP doses tested, however, the F group showed a significant- Fig. 1 The effects of 2 mg/kg FK506 on locomotor activity (top) and on stereotyped behavior (bottom) induced by 1, 2, 4 and 8 mg/kg of MAP. The T group (open circles) was given Tween 60 followed by MAP. The F group (closed circles) was treated with FK506 followed by MAP. Values are means±SEM (n=9 for each). Note significant differences (*P<0.05, **P<0.01 and ***P<0.001) between T and F groups ly lower score than the T group (P<0.05 for 1 mg/kg; P<0.01 for 2 mg/kg; P<0.001 for 4 mg/kg; P<0.05 for 8 mg/kg). Both groups showed similar stereotyped behavior scores after saline injection.
Effects of various FK506 doses (0.1, 2, 5 and 10 mg/kg) on responses to 2 mg/kg MAP
When saline was given after injection of FK506 (S group), all animals showed similar locomotor activity and stereotyped behavior scores, irrespective of the dose of FK506 (Fig. 2, top and bottom) . When MAP was given after FK506 (M group), all animals showed marked increases in both locomotor activity and stereotyped behavior scores compared to S group animals receiving the corresponding dose of FK506 (P<0.0001 for each of the FK506 doses in both behavior patterns). In the M group, animals pretreated with 0.1, 2, 5 and 10 mg/kg FK506 showed significant reductions of MAP-induced locomotor activity as compared with those receiving saline alone (P<0.05 for 0.1 mg/kg; P<0.01 for 2 mg/kg and 5 mg/kg; P<0.001 for 10 mg/kg). The scores of stereotyped behavior in animals pretreated with 0.1, 2, 5 and 10 mg/kg of FK506 were markedly lower than the value of animals receiving saline alone (P<0.01 for 0.1 mg/kg; P<0.001 for 2 mg/kg, 5 mg/kg and 10 mg/kg). The suppressive effects of FK506 on locomotor activity and the intensity of stereotyped behavior were dose-dependent [F(1,40)=13.185, P<0.01 for locomotor activity; F(1,40)= 214.283, P<0.001 for stereotyped behavior].
Experiment 2: effects of FK506 on development of behavioral sensitization
The T/S and F/S groups showed similar levels of locomotor activity and stereotyped behavior after the first injection. The T/S and F/S groups showed no overt development of either type of behavior during the scheduled When animals were challenged with 1 mg/kg MAP 1 week after the last treatment, the locomotor activity score in the T/M group was significantly greater than those of the other three groups (**P<0.01). Also, the intensity of stereotyped behavior in the T/M group was markedly higher than those of the other three groups (***P<0.001) five injections (Fig. 3) . The F/M group showed significantly greater changes in locomotor activity and stereotyped behavior after the first injection than the T/S and F/S groups (P<0.05 for both types of behavior). In this group, subsequent injections led to gradual increases in locomotor activity or stereotyped behavior. The T/M group showed markedly greater amount of changes in locomotor activity and stereotyped behavior than the other three groups after the first injection (P<0.01 for both types of behavior). Similarly to the animals given 1-8 mg/kg MAP (see Fig. 1 ), the T/M group showed an inverted U-shaped locomotor activity curve. The level of stereotyped behavior in the T/M group increased in a progressive manner.
When 1 mg/kg MAP was given 1 week after the last treatment, the T/S, F/S and F/M groups showed a similar, and insignificantly different, amount of locomotor activity and stereotyped behavior (Fig. 3, top and 
Discussion
The animal movement analysis system (Scanet SV-10) used in the present study can objectively measure locomotor activity (Asakura et al. 1992 ), but it cannot evaluate stereotyped behavior, so we subjectively assessed the intensity of stereotyped behavior using the criteria reported by Akiyama et al. (1982) .
In experiment 1, there were no significant differences in either locomotor activity or intensity of stereotyped behavior between the groups administered Tween 60 (vehicle of FK506) or 2 mg/kg FK506 followed by treatment with saline. In addition, FK506 given at a dose of 0.1, 2, 5 or 10 mg/kg did not alter locomotor activity or stereotyped behavior after saline injection. These results suggest that FK506 exerted no overt effect per se on locomotion or stereotyped behavior. It has previously been shown that locomotor activity induced by MAP forms an inverted U-shaped response curve, with increased stereotyped behavior at higher doses (Iyo et al. 1995) . The present results confirmed these findings: when the animals pretreated with Tween 60 were given MAP at a dose of 1, 2, 4 or 8 mg/kg, an inverted U-shaped response curve with the highest activity at the dose of 2 mg/kg was observed. An inverted U-shaped response curve to MAP was also observed in the animals pretreated with FK506, with the highest activity occurring at the dose of 4 mg/kg MAP. When the locomotor activity counts were compared between animals pretreated with Tween 60 and FK506, the score at 2 mg/kg MAP was significantly low in animals receiving FK506, but that at 8 mg/kg MAP was markedly increased in animals receiving FK506. These findings suggested that FK506 causes a shift of the inverted U-shaped response curve of MAP-induced locomotion toward the area of higher MAP dose.
Unlike the results of analysis of changes in locomotion, the intensity of stereotyped behavior was dosedependently increased when animals pretreated with Tween 60 were given MAP. This type of response was also observed in animals pretreated with 2 mg/kg FK506; however, these animals showed significantly reduced stereotyped behavior compared with those pretreated with Tween 60. Consequently, we concluded that pretreatment with 2 mg/kg FK506 significantly modified the locomotor activity and stereotyped behavior scores induced by 1-8 mg/kg MAP in a different manner. The results of experiment 1 also showed that pretreatment with 0.1-10 mg/kg FK506 dose-dependently reduced both the locomotor activity and stereotyped behavior scores induced by 2 mg/kg MAP. Taken together, these results suggest that FK506 can suppress or modify the locomotor activity and stereotyped behavior induced by MAP.
In experiment 2, animals that received repeated injections of 2 mg/kg FK506 and 2 mg/kg MAP for 5 days demonstrated significant decreases in both locomotor activity and stereotyped behavior following re-administration of 1 mg/kg of MAP, compared to animals given daily injections of Tween 60 and MAP. This result suggests that FK506 attenuates the development of behavioral sensitization to MAP. Since FK506 is a specific inhibitor of calcineurin (Hemenway and Heitman 1999) , calcineurin may be involved in the MAP-induced behavioral changes and sensitization.
Since amphetamine (Robinson and Becker 1986; Kalivas and Stewart 1991; Wolf et al. 1994 ) causes behavioral changes and the development of behavioral sensitization mainly via pre-and/or postsynaptic dopaminergic systems, one might assume that FK506 exerts an inhibitory effect on dopamine release. However, FK506 actually enhances dopamine release by inactivating calcineurin, which inhibits dopamine release at presynaptic sites by inactivating synapsin I (Iwata et al. 1997; Snyder et al. 1998) . Therefore, some mechanism other than the synaptic transmission of dopamine may participate in the effects of FK506 observed here.
Previous studies have shown that an increase in the cAMP level by exogenous manipulation can suppress MAP-induced behavioral changes and the development of behavioral sensitization in rats (Iyo et al. 1995 (Iyo et al. , 1996 , although MAP may not change the cAMP concentration in the brain (Iyo et al. 1996) . Since calcineurin may have antagonistic effects against intracellular cAMP transmission in dopaminergic systems (Nishi et al. 1997) , FK506 may augment the action of intracellular cAMP, resulting in the inhibition of behavioral changes and sensitization. As mentioned above, FK506 may activate dopamine release from presynaptic sites. Nevertheless, in this study, FK506 suppressed MAP-induced behavioral changes and sensitization. Therefore, the postsynaptic effects of FK506 appeared to be predominant over the presynaptic effects.
MAP stimulates synthesis of nitric oxide (NO), which may be involved in the MAP-induced behavioral chang-es and behavioral sensitization (Abekawa et al. , 1995 . Conversely, the inhibition of NO synthesis has been shown to attenuate MAP-induced stereotyped behavior (Abekawa et al. 1997) . The activation of calcineurin appears to stimulate NO synthesis (Snyder et al. 1998) , while FK506 may prevent glutamate-induced activation of NO synthesis (Dawson et al. 1993 ). Therefore, FK506 may partly attenuate MAP-induced behavioral changes and sensitization by blocking the calcineurin-mediated activation of NO synthesis.
As mentioned above, the results of the present study indicated statistically significant effects of FK506 on MAP-induced locomotor activity and stereotyped behavior. However, 2 mg/kg FK506 appeared to have modest effects on locomotor activity and on stereotyped behavior induced by doses of 1-8 mg/kg MAP, as determined from the rightward shift of the inverted U-shaped response curve without total suppression, and from the progressive intensification of stereotyped behavior without marked suppression. In addition, when the effects of 0.1-10 mg/kg FK506 on 2 mg/kg MAP were tested, neither the locomotor activity nor stereotyped behavior returned to baseline levels even at the highest dose of FK506. During the course of repetitive administration of 2 mg/kg FK506 along with 2 mg/kg MAP, the complete attenuation of both locomotor activity and stereotyped behavior was not observed. However, when animals that had been treated with a combination of 2 mg/kg FK506 and 2 mg/kg MAP were given 1 mg/kg MAP 1 week after the last treatment, the levels of locomotor activity and stereotyped behavior were similar to those in animals treated with combination of FK506/saline or Tween 60/saline. Thus, unlike the acute responses that were modestly attenuated, behavioral sensitization to MAP was completely suppressed by FK506. This suggests different roles of FK506 and calcineurin in the mechanisms underlying behavioral acute responses and sensitization to MAP. Repeated infusion of amphetamine into the ventral tegmental area (A10/A9 region) was reported to enhance behavioral responses to subsequent systemic administration of amphetamine, while the same treatment of the nucleus accumbens had no such effect (Kalivas and Weber 1988) . A recent study showed that infusion of an NMDA antagonist into the ventral tegmental area, but not the nucleus accumbens, prior to amphetamine preexposure injections dose-dependently blocked the induction of behavioral sensitization (Vezina and Queen 2000) . These findings suggested that the ventral tegmental area is a critical site for the development of behavioral sensitization, while the nucleus accumbens may be essential for production of the acute responses by amphetamine (see review by Kalivas and Stewart 1991) . In the ventral tegmental area, activation of NMDA receptors located on the dopaminergic cell bodies may play an important role in the development of behavioral sensitization (Karler et al. 1991; Wolf et al. 1994; Cador et al. 1999) . In the present study, FK506 might have disrupted the function of NMDA receptors in the ventral tegmental area, thereby preventing behavioral sensitization. However, this was unlikely because FK506 prolongs the duration of opening of NMDA receptor channels (Lieberman and Mody 1994) . It is not known how FK506 exerts different effects on behavioral sensitization and the acute response to MAP. However, our results were not in conflict with the general concept that behavioral sensitization has a different neurobiological basis to the acute responses to MAP or amphetamine (Kalivas and Stewart 1991; Karler et al. 1991; Wolf et al. 1994; Cador et al. 1999; Vezina and Queen 2000) , which in turn suggests the possible involvement of calcineurin.
Another immunosuppressive agent, cyclosporin-A, also inhibits calcineurin (Liu et al. 1991; Dawson et al. 1994) , and this agent increases spontaneous locomotor activity in rats, in addition to enhancing amphetamineinduced hyperlocomotion (Borlongan et al. 1995) . The discrepancies in the behavioral consequences between the report of Borlongan et al. (1995) and the present study could have been related to differences in experimental design. In the study reported by Borlongan et al. (1995) , both male and female Sprague-Dawley rats were given cyclosporin-A daily for over 3 weeks. Subsequently, nocturnal locomotor activity and the effects of amphetamine on the nocturnal behavior were tested. In our experiments, male Wistar rats were used, and acute behavioral responses and behavioral sensitization were tested by measurement of diurnal locomotion and stereotyped behavior.
Obviously, further studies are needed to define the involvement of calcineurin in MAP-induced behavioral changes and sensitization. However, the data available at present suggest that calcineurin plays an important role in both of these MAP-related phenomena, especially in the development of behavioral sensitization.
